S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

OncLive® On Air - Un podcast de OncLive® On Air

Essayez Nextory gratuitement pendant un mois.

Essayez Nextory gratuitement pendant un mois.

Un univers rempli de livres audio, cliquez ici pour essayer

 Sponsored
Podcast artwork

Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.

Visit the podcast's native language site